VRTX vs AMGN
VRTX and AMGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | AMGNAmgen Inc. |
|---|---|---|
| Market cap | $130.42B | $203.14B |
| P/E (TTM) | 30.0 | 23.3 |
| P/B | 6.44 | 17.38 |
| P/S | 10.9x | 5.5x |
| Dividend yield | — | 2.52% |
| Revenue | $12.59B(TTM) | $38.09B(TTM) |
| Revenue growth (YoY) | 8.9% | 10.0% |
| Net income | $4.41B(TTM) | $8.74B(TTM) |
| Earnings growth (YoY) | 838.1% | 88.5% |
| EPS, diluted | $17.17(TTM) | $16.10(TTM) |
| EBIT margin | 34.8% | 24.7% |
| ROE | 19.5% | 66.0% |
| ROIC | 25.0% | 15.1% |
| 1y total return | +31.0% | +40.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: VRTX vs AMGN
| Metric | VRTX | AMGN |
|---|---|---|
| End value | $62.7K | $33.5K |
| Total return | +526.8% | +235.2% |
| CAGR | +19.4% | +12.4% |
| Volatility | 32.7% | 25.0% |
| Sharpe | 0.58 | 0.43 |
| Sortino | 0.86 | 0.63 |
| Max drawdown | -41.6% | -24.9% |
Based on 2600 common trading days, 2016-05-12 → 2026-09-15 · risk-free 4.11% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)